Oncology

Dacarbazine medac

Product Description

The cytostatic drug dacarbazine belongs to the series of alkylating substances. By intercalation into the DNA, the substance causes strand breaks and inhibits nucleic acid and protein synthesis and cell division. Dacarbazine has a non-specific effect on cell cycle phases.

Active Ingredient

Dacarbazine citrate

Mode of Action

Enzymatic conversion into the active metabolites. Further metabolisation occurs spontaneously. Alkylation of the DNA and RNA as a result of the created methyl carbonium ion.

Indication

Treatment of patients with metastasized malignant melanoma
Advanced Hodgkin's disease
Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma)

Dosage

Powder for solution for injection/infusion:

100 mg
200 mg

Powder for solution for infusion:

500 mg
1000 mg

Not all pack sizes may be marketed.

Materials

Abbreviated product information

Open link

Discover more

Rheumatology

Key rheumatological treatment improved

Rheumatic diseases imply a range of chronic treatment needs across a broad spectrum of patients. With the optimisation of a key treatment in this area, medac has succeeded in bringing a significant improvement to patients' quality of life.

Find out more

Urology

Addressing unmet needs with urological therapies

Urology is a focus area of highest importance for medac. We have been active in this field from almost the very beginning of our company and are focused on supplying a range of proprietary products that address a variety of unmet therapeutic needs.

Find out more

Hematology

Innovative and life-saving treatment options

Hematology is a focus area of high importance for medac. To find new treatment approaches for rare diseases, medac addresses critical needs in hematology and has developed innovative products for therapies before and after stem cell transplantation.

Find out more